Latest Multiple Sclerosis (MS) News

ODAC meeting to discuss RCC imagingFDA's Oncologic Drugs Advisory Committee (ODAC) will meet on July 25 to discuss the extent of useful clinical information provided by an imaging test for clear cell renal cell carcinoma (RCC) before surgery. FDA will also review the development strat...

CIRM awards $69 million in grantsThe California Institute for Regenerative Medicine awarded $69.4 million in 21 Early Translational III awards across 11 universities and institutions. CIRM said three of the projects also will receive collaborative funding from the governments of Aus...

Stem cell-growing surface enables bone repairUniversity of Michigan researchers have proven that a special surface, free of biological contaminants, allows adult-derived stem cells to thrive and transform into multiple cell types. Their success brings stem cell therapies another step closer.

XenoPort submits IND application to commence XP23829 clinical studiesXenoPort has submitted an Investigational New Drug (IND) application to the FDA to commence XP23829 clinical studies as a potential treatment for relapsing-remitting multiple sclerosis (RRMS).

Special surface allows adult-derived stem cells to thrive and transform into multiple cell typesUniversity of Michigan researchers have proven that a special surface, free of biological contaminants, allows adult-derived stem cells to thrive and transform into multiple cell types. Their success brings stem cell therapies another step closer.

TB4 Provides Both Neuroprotection and Neurorestoration When Administered Shortly after Traumatic Brain Injury in Rat ModelRegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) (“the Company” or “RegeneRx”) reported that data showing that Thymosin beta 4 (Tβ4) “provides both neuroprotection and neurorestoration after traumatic brain injury (TBI),” was published in the current (May 2012) edition of the Journal of Neurosurgery, 116:1081–1092. As re...

ImmunoCellular Therapeutics Receives Approval for NYSE MKT ListingImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, announced today that its common stock has been approved for listing on the NYSE: MKT. Trading is expected to commence on the NYSE: MKT on Wednesday, May 30th, 2012 under the...

Current pharma pricing policy will hurt both patients and industry in the long run, assert pharma expertsPharmaceutical analysts in India and the UK believe cost-based pricing is not suitable to safeguard the interests of patients as well as the pharmaceutical industry. In their opinion, the regulatory authorities have wrongly been focusing on price con...

immatics Wins 2012 TiE50 AwardTUEBINGEN, Germany, May 25, 2012 /PRNewswire/ -- immatics chosen as a leading company in the life sciences category by the world's largest entrepreneurial network immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that it has been named a 2012 TiE50 winner. These prestigious awards re...

FDA completes safety review of MS drugThe multiple sclerosis drug fingolimod (Gilenya, Novartis) is now contraindicated for use in patients with certain pre-existing or recent heart conditions or stroke, or who are taking certain antiarrhythmic medications, according to FDA

IDA's New Dental Marketing Control Panel Features Easy Email Management To Generate LeadsNew dental marketing websites from Internet Dental Alliance, Inc. (IDA) offer email options that are easy to manage from one online location. (PRWEB) May 24, 2012 New dental marketing websites from Internet Dental Alliance, Inc. (IDA) feature optional online email management that's easy to set up and maintain. From IDA's online Control Panel, dentists can create a virtual "Post Office” for eac...

Millennium and Takeda Announce Presentations for Key Investigational Molecules at American Society of Clinical Oncology Annual Meeting- Presentations highlight first oral proteasome inhibitor in clinical trials in multiple myeloma patients -CAMBRIDGE, Mass., May 23, 2012 – with its parent company Takeda Pharmaceutical Company Limited (TSE:4502) today announced that 101 abstracts featuring the Company’s oncology molecules have been accepted at the annual meeting of the American Socie...

UC San Diego researchers receive new CIRM funding(University of California - San Diego) Five scientists from the University of California, San Diego and its School of Medicine have been awarded almost $12 million in new grants from the California Institute for Regenerative Medicine to conduct stem...

Bone Repair Using Stem-Cell-Growing SurfaceUniversity of Michigan researchers have proven that a special surface, free of biological contaminants, allows adult-derived stem cells to thrive and transform into multiple cell types. Their success brings stem cell therapies another step closer. To...

Provost Umphrey: More Retired Players Added to Lawsuit Against NFLSuit States Multiple Concussions Cause Dementia and Permanent Brain Damage Houston, TX (PRWEB) May 24, 2012 Fourteen additional players joined the roster of retired football players that allege in the suit "the NFL did not take reasonable steps necessary to protect its players from devastating head injuries, and did everything in its power to hide the issue and mislead players concerning the risk...

‘My Pain Diary: Chronic Pain Management’ Update to Make Tracking Multiple Chronic Conditions on your iPhone EasierMy Pain Diary: Chronic Pain Management ver. 1.990 will be available in the iTunes App Store on Thursday May 31st. Created and actively maintained by a RSD/CRPS patient, MPD is an iPhone app that empowers patients of chronic pain and illness to document, track, report, and manage their condition. Columbus, OH (PRWEB) May 24, 2012 My Pain Diary: Chronic Pain Management (MPD) is used by thousands of...

PDI, Inc. Announces New Business Win Valued at $57 MillionPARSIPPANY, N.J., May 24, 2012 /PRNewswire/ -- PDI, Inc. (Nasdaq: PDII) today announced the signing of a contract with a new customer to provide promotional services across PDI's multiple communications channels that will target primary care physicians. The contract is subject to FDA product approval. The contract is expected to generate total revenue to PDI of approximately $57 million over...

Recovery From Multiple Sclerosis By Growth Factor In Stem CellsThe online edition of Nature Neuroscience reports that researchers from the Case Western Reserve University School of Medicine have discovered that a substance within growth promoting human mesenchymal stem cells seems to spur restoration of nerves a...

TriZetto’s Enterprise Solution Supports CareOregon’s Growth, Multiple Lines of Business and Enhanced EfficiencyThe TriZetto Group, Inc., today announced that CareOregon has met critical deadlines, grown its business and improved administrative efficiency with the help of a technology-enabled solution from TriZetto. TriZetto’s enterprise

XenoPort Submits Investigational New Drug Application for XP23829 as a Potential Treatment of RRMSXenoPort, Inc. (Nasdaq:XNPT) announced today that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to begin clinical studies of XP23829 as a potential treatment for relapsing-remitting multiple sclerosis (RRMS). Following clearance of the IND by the FDA, the first Phase 1 clinical trial to be con...

Questcor Pharmaceuticals to Present at Jefferies 2012 Global Healthcare ConferenceANAHEIM, Calif., May 24, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) announced today that executive management will present at the Jefferies 2012 Global Healthcare Conference in New York on June 6, 2012 at 5:00 a.m. PT / 8:00 a.m. ET. A live webcast and subsequent archived replay of the presentation will be accessible at http://ir.questcor.com/events.cfm. The replay w...

New Senior Vice President of Operations for Aegis LivingREDMOND, Wash., May 24, 2012 /PRNewswire/ -- Aegis Living, a national leader in assisted living and memory care, is pleased to announce the hiring of Michael Grisar, Senior Vice President of Operations. After completing a very thorough training and on-boarding program Michael will have operational responsibility for one of Aegis Living's three west-coast regions. In this role he w...

Health Canada approves Biogen Tysabri label changeThe Health Canada has approved a label change for Biogen Idec's Tysabri to include anti-JC virus (JCV) antibody status as a risk factor for patients with multiple sclerosis (MS).

Marijuana Relieves Spasticity but Affects Cognition in MSSmoking marijuana may provide relief from spasticity and pain in patients with multiple sclerosis, but the benefits come with adverse cognitive effects. Medscape Medical News

Now Hiring Experienced Registered Nurses at Florida HospitalThursday, May 31, 2012 9:00 am - 2:00 pm; the Florida Hospital Experienced RN Hiring Event is being hosted at all hospital locations: Altamonte, Apopka, Celebration, East Orlando, Kissimmee, Orlando, Winter Park. For more information about our event and to register to speak directly to a Nurse Recruiter, please visit: http://www.nursingcareerfair.net. Orlando, FL (PRWEB) May 24, 2012 Florida Hosp...

0 1 2 3 4 ›»

buy Multiple Sclerosis (MS) market research data and corporate reports now Advertisement